Nile AI

About Nile AI

Nile AI, Inc. operates as a digital health company with a focused mission to make the journey for epilepsy patients more predictable. The company was established as an independent entity in January 2021, spun-off from the biopharmaceutical company UCB, which is a leader in epilepsy drug development. UCB invested €25 million ($29.3 million) in Nile, becoming the majority shareholder. The company is led by CEO Dr. Leo Petrossian, who notes that the firm was created to address systemic problems in epilepsy care management from a more holistic perspective. His personal connection to the field comes from his wife, a neurologist, which provides him with insight into the unpredictable nature of living with epilepsy.

The core of Nile's business is a digital epilepsy care management platform that functions as an extension of the healthcare provider. The platform aims to shorten the path to optimal treatment by gathering and connecting fragmented data to better predict patient outcomes. It serves people living with epilepsy, their caregivers, and their healthcare providers (HCPs). Revenue is generated through partnerships within the epilepsy ecosystem.

Nile's product consists of two main components: a patient-facing mobile application and a portal for HCPs. For patients, the app is a tool to manage medication regimens, track symptoms, receive personalized alerts, and access educational content, connecting them with their care team between appointments. The HCP portal provides a dashboard with at-a-glance status updates of their patients, allowing for remote support and data-driven decision-making. A key feature is the medication titration manager, which assists clinicians in creating complex titration schedules. Within its first year, Nile achieved ISO 13485 certification, is FDA registered, and is HIPAA compliant, establishing its platform as a medical-grade quality system. The Epilepsy Foundation has also named Nile as its preferred seizure diary app.